Ephedra lawsuit
This article was originally published in The Tan Sheet
Executive Summary
NVE Pharmaceuticals may not supplement FDA's administrative record as it proceeds with legal allegations against the agency's ephedra ban, a Third Circuit Court of Appeals judge rules Feb. 7. Thus, NVE may not provide expert affidavits or testimony and may not conduct discovery. The ruling affirms that of an August 2004 ruling by a district judge in Newark, N.J. federal court where the case was originally filed. The case is remanded to the district court for further proceedings in accordance with the opinion of the appellate court. NVE filed the complaint against FDA in March 2004 alleging that the agency could not ban supplements containing ephedrine alkaloids because it did not meet the burden of proof required by DSHEA (1"The Tan Sheet" March 15, 2004, p. 8). The agency also is appealing a Utah federal court ruling in a separate suit against its ephedra ban that was filed by Nutraceutical Corp (2"The Tan Sheet" Nov. 14, 2005, p. 4)...
You may also be interested in...
“No Evidence” Exists That Ephedra Ban Shifted Burden Of Proof, Agency Says
No evidence has been presented that FDA's use of a risk/benefit analysis in its decision to ban ephedra shifted the burden of proof onto industry, the agency says
NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says
NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.